Group One Trading’s Adamas Pharmaceuticals ADMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-48,700
Closed -$239K 9186
2021
Q3
$239K Sell
48,700
-700
-1% -$3.4K ﹤0.01% 4987
2021
Q2
$261K Buy
49,400
+20,900
+73% +$108K ﹤0.01% 4936
2021
Q1
$137K Buy
28,500
+28,200
+9,400% +$147K ﹤0.01% 5368
2020
Q4
$1K Sell
300
-15,000
-98% -$64.2K ﹤0.01% 6387
2020
Q3
$63K Buy
15,300
+14,200
+1,291% +$54.9K ﹤0.01% 4501
2020
Q2
$3K Sell
1,100
-100
-8% -$294 ﹤0.01% 5525
2020
Q1
$3K Sell
1,200
-63,500
-98% -$285K ﹤0.01% 4929
2019
Q4
$245K Buy
64,700
+62,500
+2,841% +$299K ﹤0.01% 3025
2019
Q3
$11K Sell
2,200
-54,500
-96% -$336K ﹤0.01% 4584
2019
Q2
$352K Buy
56,700
+8,600
+18% +$49.5K ﹤0.01% 2453
2019
Q1
$342K Buy
48,100
+32,000
+199% +$288K ﹤0.01% 2256
2018
Q4
$137K Sell
16,100
-5,700
-26% -$74.1K ﹤0.01% 2965
2018
Q3
$436K Buy
21,800
+400
+2% +$9.39K ﹤0.01% 2397
2018
Q2
$553K Sell
21,400
-18,200
-46% -$504K ﹤0.01% 2213
2018
Q1
$946K Sell
39,600
-12,700
-24% -$400K 0.01% 1568
2017
Q4
$1.77M Buy
52,300
+23,800
+84% +$665K 0.01% 1272
2017
Q3
$603K Buy
28,500
+27,500
+2,750% +$504K 0.01% 1933
2017
Q2
$17K Buy
+1,000
New +$16.5K ﹤0.01% 4020

Group One Trading's ADMS Position: Q4 2021 in Review

Group One Trading sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 16,483 shares — an estimated $81K sold.

Group One Trading first reported a position in ADMS in Q4 2015 and held it in 13 quarters. The position peaked at $794K in Q3 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

  • Group One Trading reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Group One Trading sold 16,483 Adamas Pharmaceuticals shares in Q4 2021, an estimated $81K.
  • Group One Trading first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Group One Trading's Adamas Pharmaceuticals position peaked at $794K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Group One Trading's 13F filing for Q4 2021, filed 11 Feb 2022.